Compare BLTE & PECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | PECO |
|---|---|---|
| Founded | 2018 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.0B |
| IPO Year | 2021 | 2010 |
| Metric | BLTE | PECO |
|---|---|---|
| Price | $163.68 | $37.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $228.89 | $44.85 |
| AVG Volume (30 Days) | 168.4K | ★ 793.7K |
| Earning Date | 11-09-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | N/A | ★ 74.51 |
| EPS | N/A | ★ 0.56 |
| Revenue | N/A | ★ $726,594,000.00 |
| Revenue This Year | N/A | $4.47 |
| Revenue Next Year | N/A | $6.69 |
| P/E Ratio | ★ N/A | $67.18 |
| Revenue Growth | N/A | ★ 9.86 |
| 52 Week Low | $72.65 | $32.98 |
| 52 Week High | $200.00 | $44.38 |
| Indicator | BLTE | PECO |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 33.04 |
| Support Level | $167.28 | $36.55 |
| Resistance Level | $172.02 | $40.80 |
| Average True Range (ATR) | 5.28 | 0.57 |
| MACD | -0.86 | 0.07 |
| Stochastic Oscillator | 39.80 | 17.06 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.